指南与共识药疹与重症皮肤不良反应皮肤肿瘤

免疫检查点抑制剂所致皮肤不良反应管理欧洲推荐:EADV「癌症患者皮肤病学」工作组立场声明

European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2021-12-15

欧洲皮肤病与性病学会(EADV)「癌症患者皮肤病学」工作组发布立场声明,针对免疫检查点抑制剂(ICI)所致皮肤不良反应(dirAEs),整合已发表数据的临床经验,按皮疹表型提出皮肤科来源的特定治疗推荐,并附证据等级与推荐等级。

要点

  • 皮肤irAEs约见于40%接受免疫治疗的患者。
  • 表现包括斑丘疹、银屑病样、苔藓样和湿疹样皮疹、自身免疫性大疱病、色素异常、瘙痒、口腔黏膜病变、毛发和甲改变及少见潜在危及生命的毒性。
  • 管理基本原则是干预应兼顾缓解皮肤毒性症状体征与维持肿瘤治疗不受阻。

核心结论

  • EADV工作组按皮肤毒性表型发布特定治疗推荐,并给出证据等级与推荐等级。

研究设计与样本

  • EADV「癌症患者皮肤病学」工作组立场声明,整合迄今已发表数据的临床经验。

主要发现

  • 皮肤irAEs约见于40%接受免疫治疗的患者。
  • 主要包括斑丘疹、银屑病样、苔藓样和湿疹样皮疹、自身免疫性大疱病、色素异常、瘙痒、口腔黏膜病变、毛发和甲改变,以及少数少见且潜在危及生命的毒性。

关键数值与推荐

  • 推荐按每种特定皮肤irAEs的定量和定性特征制定,并附证据等级与推荐等级。
  • 管理基本原则为干预应 tailored 于缓解皮肤毒性症状体征与维持肿瘤治疗不受阻之间的平衡。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed by the development of immune-related adverse events (irAEs). Dermatologic irAEs (dirAEs) appear in about 40% of patients undergoing immunotherapy and mainly include maculopapular, psoriasiform, lichenoid and eczematous rashes, auto-immune bullous disorders, pigmentary disorders, pruritus, oral mucosal lesions, hair and nail changes, as well as a few rare and potentially life-threatening toxicities. The EADV task force Dermatology for Cancer Patients merged the clinical experience of the so-far published data, incorporated the quantitative and qualitative characteristics of each specific dirAEs, and released dermatology-derived, phenotype-specific treatment recommendations for cutaneous toxicities (including levels of evidence and grades of recommendation). The basic principle of management is that the interventions should be tailored to serve the equilibrium between patients' relief from the symptoms and signs of skin toxicity and the preservation of an unimpeded oncologic treatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement. J Eur Acad Dermatol Venereol. 2021. PMID: 34910332. doi:10.1111/jdv.17855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。